GRACE SCIENCE FOUNDATION: Form 990, tax year 2024
View the entire original 990 at ProPublica ↗
- Organization
- GRACE SCIENCE FOUNDATION (EIN 46-5727883)
- Tax period
- 2024-01-01 to 2024-12-31
- Filed
- 2025-10-16
- IRS object ID
- 202512899349300541
- Schema version
- 2024v5.2
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2025-10-16T08:48:57-04:00 | ReturnTs |
| Tax Period End | 2024-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | WITHUMSMITHBROWNPC | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 6101 BOLLINGER CANYON RD STE 400 | AddressLine1Txt |
| City | SAN RAMON | CityNm |
| State Abbreviation | CA | StateAbbreviationCd |
| ZIP | 94583 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2024-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 465727883 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | GRACE SCIENCE FOUNDATION | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| In Care Of | % GRACE SCIENCE FOUNDATION | InCareOfNm |
| Business Name Control | GRAC | BusinessNameControlTxt |
| Phone | 6507464591 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 873 SANTA CRUZ AVENUE SUITE 200 | AddressLine1Txt |
| City | MENLO PARK | CityNm |
| State Abbreviation | CA | StateAbbreviationCd |
| ZIP | 94025 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | MATTHEW R WILSEY | PersonNm |
| Person Title | PRESIDENT | PersonTitleTxt |
| Phone | 6507464591 | PhoneNum |
| Signature | 2025-11-15 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IRS Responsible Prty Info Curr | Yes (true) | IRSResponsiblePrtyInfoCurrInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | RICHARD RUVELSON | PreparerPersonNm |
| PTIN | P00234075 | PTIN |
| Phone | 9252779100 | PhoneNum |
| Preparation | 2025-11-15 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2024 | TaxYr |
| Build TS | 2025-03-06 01:10:19Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | MATTHEW R WILSEY | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 873 SANTA CRUZ AVENUE SUITE 2 | AddressLine1Txt |
| City | MENLO PARK | CityNm |
| State Abbreviation | CA | StateAbbreviationCd |
| ZIP | 94025 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $943,011 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | www.gracescience.org | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2014 | FormationYr |
| Legal Domicile State | CA | LegalDomicileStateCd |
| Activity Or Mission | SEE PART III LINE 1 | ActivityOrMissionDesc |
| Voting Members Governing Body | 7 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 7 | VotingMembersIndependentCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Total Volunteers | 0 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $783,225 | PYContributionsGrantsAmt |
| CY Contributions Grants | $869,699 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $0 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $43,401 | PYInvestmentIncomeAmt |
| CY Investment Income | $73,312 | CYInvestmentIncomeAmt |
| PY Other Revenue | $0 | PYOtherRevenueAmt |
| CY Other Revenue | $0 | CYOtherRevenueAmt |
| PY Total Revenue | $826,626 | PYTotalRevenueAmt |
| CY Total Revenue | $943,011 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $1,133,449 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $1,342,330 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $0 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $0 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $0 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $155,725 | PYOtherExpensesAmt |
| CY Other Expenses | $177,056 | CYOtherExpensesAmt |
| PY Total Expenses | $1,289,174 | PYTotalExpensesAmt |
| CY Total Expenses | $1,519,386 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$462,548 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$576,375 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $2,790,274 | TotalAssetsBOYAmt |
| Total Assets EOY | $2,224,370 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $42,997 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $1,004 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $2,747,277 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $2,223,366 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | THE MISSION OF THE FOUNDATION IS TO SUPPORT AND FUND THE DEVELOPMENT OF LIFE-SAVING TREATMENT FOR PATIENTS THAT ARE DEFICIENT IN THE N-GLYCANESE ENZYME AND THOSE SUFFERING FROM RELATED GENETIC DISEASES. THE ACTIVITIES OF THE FOUNDATION WILL INVOLVE PROVIDING GRANT FUNDING TO HOSPITALS AND MEDICAL RESESARCH FACILITIES WHICH ARE CONDUCTING MEDICAL RESEARCH IN VARIOUS FIELDS RELATING TO THE SEARCH FOR UNDERSTNADING AND TREATMENT OF THIS CONDITION, FOSTERING COLLABORATION BETWEEN ACADEMIA, RESEARCH INSTITUTIONS, HOSPITALS, PRIVATE COMPANIES, AND GOVERNMENTAL AGENCIES. | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $452,697 | ExpenseAmt |
| Grant | $452,697 | GrantAmt |
| Desc | Baylor College of Medicine NGLY1 Natural History Study (Bernhard Suter) Team is conducting a natural history study to define the clinical spectrum of the disease and its progression, and define biomarker endpoints for use in therapeutic trials. This study is led by Dr. Bernhard Suter, MD, a child neurologist and medical geneticist. The study is collecting longitudinal measures of movement concurrently with clinical and biomarker measures to define aspects of gait and movement that are most affected in the disorder, characterize progression of the disease, select clinical features for performing longitudinal assessments, and inform clinical endpoint development for therapeutic trials. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $352,945 | ExpenseAmt |
| Grant | $352,945 | GrantAmt |
| Desc | Psychogenics Inc. Team has imported and is analyzing mouse and rat models of NGLY1 Deficiency for testing of candidate therapies. Team has conducted several studies using an NGLY1 knockout rat model to test phenotypic rescue using candidate small molecule therapies (both novel and approved drugs). | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $203,574 | ExpenseAmt |
| Grant | $203,574 | GrantAmt |
| Desc | THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (YAN LAB) Team continues work generating and characterizing several mouse models of NGLY1 Deficiency, including models in which the gene is inactivated in certain tissues and conditionally after birth. These mouse models have allowed them to characterize neurological phenotypes including neuronal loss, neuropathological changes, inflammation, sensory and motor defects, and disease associated biomarkers, all of which are also observed in NGLY1 Deficiency patients These animal models provide a foundation for testing candidate therapies, including gene therapies and small molecule drugs. The team has also found that NGLY1 Deficiency in mice triggers a specific innate immune pathway mediated by the cGAS/STING pathway. Using genetic and pharmacological approaches, the team has uncovered three different targets that can be modulated to reduce disease associated phenotypes and improve survival. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp (14 entries)
| ExpenseExpenseAmt | GrantGrantAmt | DescDesc |
|---|---|---|
| $80,637 | $80,637 | The University of North Carolina (Hantman Lab) |
| $68,025 | $68,025 | Charles River Laboratories |
| $49,108 | $49,108 | Boston Children's Hospital (Yu Lab) |
| $27,695 | $27,695 | Hilltop Lab Animals Inc. |
| $24,241 | $24,241 | Albert Einstein College of Medicine (Kaushik Lab) |
| $23,869 | $23,869 | Purdue University (Rochet Lab) |
| $20,356 | $20,356 | Pharmaron, Inc |
| $19,321 | $19,321 | Universitry of Utah (Chow Lab) |
| $10,115 | $10,115 | Standford University |
| $9,747 | $9,747 | University of Houston |
| $19,000 | $0 | Bioagilytix Labs |
| $13,904 | $0 | Transnetyx |
| $10,481 | $0 | Wuxi Apptec |
| $5,369 | $0 | MedChem Express LLC |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $381,868 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $333,114 | TotalOtherProgSrvcGrantAmt |
| Total Program Service Expenses | $1,391,084 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | false | LobbyingActivitiesInd |
| Subject To Proxy Tax | false | SubjectToProxyTaxInd |
| Donor Advised Fund | false | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | false | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | false | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | false | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | false | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | false | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | false | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | false | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | false | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | false | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (true) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividualsInd |
| Professional Fundraising | false | ProfessionalFundraisingInd |
| Fundraising Activities | false | FundraisingActivitiesInd |
| Gaming Activities | false | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | false | GrantsToIndividualsInd |
| Schedule J Required | false | ScheduleJRequiredInd |
| Tax Exempt Bonds | false | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | false | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | false | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | false | DisregardedEntityInd |
| Related Entity | false | RelatedEntityInd |
| Related Organization Ctrl Ent | false | RelatedOrganizationCtrlEntInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| IRP Document | 3 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (true) | BackupWthldComplianceInd |
| Employee | 0 | EmployeeCnt |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | false | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | false | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| Form8899 Filedind | false | Form8899Filedind |
| Form1098 C Filed | false | Form1098CFiledInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | false | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | false | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 7 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 7 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (true) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | false | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | false | MembersOrStockholdersInd |
| Election Of Board Members | Yes (true) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | false | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | false | MinutesOfGoverningBodyInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | false | LocalChaptersInd |
| Form990 Provided To Gvrn Body | false | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | false | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | false | RegularMonitoringEnfrcInd |
| Whistleblower Policy | false | WhistleblowerPolicyInd |
| Document Retention Policy | false | DocumentRetentionPolicyInd |
| Compensation Process CEO | false | CompensationProcessCEOInd |
| Compensation Process Other | false | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| Other Website | Yes (X) | OtherWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | GRACE SCIENCE FOUNDATION | PersonNm |
| Phone | 6507464591 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 873 SANTA CRUZ AVENUE SUITE 200 | AddressLine1Txt |
| City | MENLO PARK | CityNm |
| State Abbreviation | CA | StateAbbreviationCd |
| ZIP | 94025 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| No Listed Persons Compensated | Yes (X) | NoListedPersonsCompensatedInd |
Form990 Part VII Section A Form990PartVIISectionAGrp (7 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt |
|---|---|---|---|---|---|---|---|
| Matthew Wilsey | |||||||
| President | 0.0 | 0.0 | Yes (X) | Yes (X) | $0 | $0 | $0 |
| Egon Durban | |||||||
| Chief Financial Officer | 0.0 | 0.0 | Yes (X) | Yes (X) | $0 | $0 | $0 |
| KEN DRAZAN | |||||||
| Secretary | 0.0 | 0.0 | Yes (X) | Yes (X) | $0 | $0 | $0 |
| Pete Briger | |||||||
| Director | 0.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |
| Chelsea Clinton | |||||||
| Director | 0.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |
| J Taylor Crandall | |||||||
| Director | 0.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |
| Elle Stephens | |||||||
| Director | 0.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $0 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $0 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 0 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | false | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | false | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
| Cntrct Rcvd Greater Than100 K | 0 | CntrctRcvdGreaterThan100KCnt |
| All Other Contributions | $869,699 | AllOtherContributionsAmt |
| Total Contributions | $869,699 | TotalContributionsAmt |
| Total Program Service Revenue | $0 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $73,312 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $73,312 | ExclusionAmt |
Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $0 | RealAmt |
| Personal | $0 | PersonalAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $0 | FundraisingGrossIncomeAmt |
| Fundraising Direct Expenses | $0 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gaming Gross Income | $0 | GamingGrossIncomeAmt |
| Gaming Direct Expenses | $0 | GamingDirectExpensesAmt |
Net Income From Gaming NetIncomeFromGamingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Sales Of Inventory | $0 | GrossSalesOfInventoryAmt |
| Cost Of Goods Sold | $0 | CostOfGoodsSoldAmt |
Net Income Or Loss NetIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $0 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $943,011 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $73,312 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,342,330 | TotalAmt |
| Program Services | $1,342,330 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Benefits To Members BenefitsToMembersGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Comp Disqual Persons CompDisqualPersonsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Services Management FeesForServicesManagementGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $779 | TotalAmt |
| Management And General | $779 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $17,420 | TotalAmt |
| Management And General | $17,420 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $99,200 | TotalAmt |
| Management And General | $99,200 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,000 | TotalAmt |
| Management And General | $5,000 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,717 | TotalAmt |
| Management And General | $2,717 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $645 | TotalAmt |
| Management And General | $645 | ManagementAndGeneralAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $559 | TotalAmt |
| Management And General | $559 | ManagementAndGeneralAmt |
Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Payments To Affiliates PaymentsToAffiliatesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Expenses OtherExpensesGrp (3 entries)
| DescDesc | TotalTotalAmt | Management And GeneralManagementAndGeneralAmt | Program ServicesProgramServicesAmt |
|---|---|---|---|
| SHIPPING FEES | $1,782 | $1,782 | |
| TAX EXPENSE | $200 | $200 | |
| PROGRAM EXPENSES | $48,754 | $48,754 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,519,386 | TotalAmt |
| Program Services | $1,391,084 | ProgramServicesAmt |
| Management And General | $128,302 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $352,830 | BOYAmt |
| EOY | $142,773 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,437,444 | BOYAmt |
| EOY | $2,081,597 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Receivables From Officers Etc ReceivablesFromOfficersEtcGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Investments Program Related InvestmentsProgramRelatedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Intangible Assets IntangibleAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,790,274 | BOYAmt |
| EOY | $2,224,370 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $42,997 | BOYAmt |
| EOY | $1,004 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Escrow Account Liability EscrowAccountLiabilityGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Loans From Officers Directors LoansFromOfficersDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $42,997 | BOYAmt |
| EOY | $1,004 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Org Does Not Follow FASB117 | Yes (X) | OrgDoesNotFollowFASB117Ind |
Cap Stk Tr Prin Current Funds CapStkTrPrinCurrentFundsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Pd In Cap Srpls Land Bldg Eqp Fund PdInCapSrplsLandBldgEqpFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Rtn Earn Endowment Incm Oth Fnds RtnEarnEndowmentIncmOthFndsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,747,277 | BOYAmt |
| EOY | $2,223,366 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,790,274 | BOYAmt |
| EOY | $2,224,370 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | -$576,375 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $52,464 | NetUnrlzdGainsLossesInvstAmt |
| Method Of Accounting Cash | Yes (X) | MethodOfAccountingCashInd |
| Accountant Compile Or Review | false | AccountantCompileOrReviewInd |
| FS Audited | false | FSAuditedInd |
| Federal Grant Audit Required | false | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,447,474 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,325,647 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,206,450 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $783,225 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $869,699 | CurrentTaxYearAmt |
| Total | $5,632,495 | TotalAmt |
Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,447,474 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,325,647 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,206,450 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $783,225 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $869,699 | CurrentTaxYearAmt |
| Total | $5,632,495 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $2,543,020 | SubstantialContributorsTotAmt |
| Public Support Total170 | $3,089,475 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $6,706 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,466 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $29,778 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $43,401 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $73,312 | CurrentTaxYearAmt |
| Total | $154,663 | TotalAmt |
Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $5,787,158 | TotalSupportAmt |
| Public Support CY170 | 0.53385 | PublicSupportCY170Pct |
| Public Support PY170 | 0.60408 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Region | East Asia and the Pacific | RegionTxt |
| Offices | 0 | OfficesCnt |
| Employee | 0 | EmployeeCnt |
| Type Of Activities Conducted | Program Services | TypeOfActivitiesConductedTxt |
| Specific Services Provided | RESEARCH | SpecificServicesProvidedTxt |
| Region Total Expenditures | $10,481 | RegionTotalExpendituresAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $10,481 | SubtotalSpentAmt |
| Total Spent | $10,481 | TotalSpentAmt |
| Transfer To Foreign Corp | false | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | false | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | false | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (13 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|
| CHARLES RIVER LABORATORIES | |||||||
| 251 BALLARDVALE STREET | WILMINGTON | MA | 01887 | 061397316 | 501(c)(6) | $68,025 | NGLY1 |
| THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTE | |||||||
| 5323 HARRY HINES BLVD | DALLAS | TX | 75390 | 756002868 | GOVERNMENT | $203,574 | NGLY1 (YAN LAB) |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | |||||||
| 1300 MORRIS PARK AVENUE | BRONX | NY | 10461 | 830621846 | 501(c)(3) | $24,241 | NGLY1 (KAUSHIK LAB) |
| HILLTOP LAB ANIMALS INC | |||||||
| 131 HILLTOP DR | SCOTTDALE | PA | 15683 | 251153656 | $27,695 | NGLY1 | |
| BAYLOR COLLEGE OF MEDICINE | |||||||
| ONE BAYLOR PLAZA BCM 200 | HOUSTON | TX | 77030 | 741613278 | 501(c)(3) | $452,697 | NGLY1 (JAFAR-NEJAD LAB) |
| PURDUE UNIVERSITY | |||||||
| 610 PURDUE MALL | WEST LAFAYETTE | IN | 47907 | 366002041 | 501(c)(3) | $23,869 | NGLY1 |
| UNIVERSITY OF HOUSTON | |||||||
| 4800 CALHOUN ROAD | HOUSTON | TX | 77204 | 746001399 | 115 | $9,747 | NGLY1 |
| PSYCHOGENICS INC | |||||||
| 215 College Rd | PARAMUS | NJ | 07652 | 141989159 | $352,945 | NGLY1 | |
| STANFORD UNIVERSITY | |||||||
| 3145 PORTER DRIVE | PALO ALTO | CA | 94304 | 941156365 | 501(c)(3) | $10,115 | NGLY1 |
| UNC CHAPEL HILL | |||||||
| 250 E Franklin St | Chapel Hill | NC | 27514 | 566001393 | 501(c)(3) | $80,637 | NGLY1 |
| Boston Children's Hospital | |||||||
| 300 LONGWOOD AVENUE | BOSTON | MA | 02115 | 042774441 | 501(c)(3) | $49,108 | NGLY1 |
| PHARMARON | |||||||
| 201 EAST JEFFERSON STREET SUITE 30 | LOUISVILLE | KY | 40202 | 208419781 | $20,356 | NGLY1 | |
| University of Utah | |||||||
| 201 S PRESIDENTS CIR RM 406 | SALT LAKE CITY | UT | 84112 | 876000525 | 115 | $19,321 | NGLY1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 8 | Total501c3OrgCnt |
| Total Other Org | 5 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Part I Description of Procedure for Monitoring Use of Funds | * BEFORE FUNDING A PRINCIPAL INVESTIGATOR, THE FOUNDATION REQUIRES A DETAILED PROPOSAL WITH OBJECTIVES AND MILESTONES. * THE PROPOSALS ARE REVIEWED BY THE FOUNDATION AND SCIENTIFIC ADVISORY BOARD. * THE PROPOSALS ARE OFTEN REVISED SEVERAL TIMES TO GET THE CORRECT FIT. * Once funded, each principal investigator submits a written summary every quarter. * This update is two to three pages in length. * The reports discuss progress, highlight roadblocks and identify where they need help. *THE FOUNDATION STEPS-IN WHERE APPROPRIATE TO MAKE SURE OBJECTIVES AND MILESTONES ARE MET. * IN ADDITION TO QUARTERLY REPORTS, THE FOUNDATION HOLDS A MONTHLY CONFERENCE CALL WHERE TWO TO THREE PRINCIPAL INVESTIGATORS PRESENT THEIR LATEST WORK. * BEYOND THE ABOVE TWO INITIATIVES, THE FOUNDATION HOLDS ONE TO TWO IN-PERSON MEETINGS PER YEAR. * DR. KEVIN LEE (CHIEF SCIENTIFIC OFFICER), DR. SELINA DWIGHT (PROGRAM MANAGER), AND MATT WILSEY(PRESIDENT) CONTACT RESEARCHERS AND PRINCIPAL INVESTIGATORS ON A REGULAR BASIS VIA EMAIL, PHONE, OR ONE ON ONE MEETINGS. THE PRESIDENT ENSURES THAT EVERY DOLLAR IS USED TO SUPPORT THE GRACE SCIENCE FOUNDATION'S MISSION. |
| PART II: | THE FOUNDATION REQUESTS AND OBTAINS TO THE BEST OF THEIR ABILITY THE FEIN'S FROM ORGANIZATIONS IT PROVIDES GRANT FUNDING. |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (22 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 1: | THE MISSION OF THE FOUNDATION IS TO SUPPORT AND FUND THE DEVELOPMENT OF LIFE-SAVING TREATMENT FOR PATIENTS THAT ARE DEFICIENT IN THE N-GLYCANESE ENZYME AND THOSE SUFFERING FROM RELATED GENETIC DISEASES. THE ACTIVITIES OF THE FOUNDATION WILL INVOLVE PROVIDING GRANT FUNDING TO HOSPITALS AND MEDICAL RESEARCH FACILITIES WHICH ARE CONDUCTING MEDICAL RESEARCH IN VARIOUS FIELDS RELATING TO THE SEARCH FOR UNDERSTANDING AND TREATMENT OF THIS CONDITION, AND FOSTERING COLLABORATION BETWEEN ACADEMIA, RESEARCH INSTITUTIONS, HOSPITALS, PRIVATE COMPANIES, AND GOVERNMENTAL AGENCIES. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | Baylor College of Medicine NGLY1 Natural History Study (Bernhard Suter)Team is conducting a natural history study to define the clinical spectrum of the disease and its progression, and define biomarker endpoints for use in therapeutic trials. This study is led by Dr. Bernhard Suter, MD, a child neurologist and medical geneticist. The study is collecting longitudinal measures of movement concurrently with clinical and biomarker measures to define aspects of gait and movement that are most affected in the disorder, characterize progression of the disease, select clinical features for performing longitudinal assessments, and inform clinical endpoint development for therapeutic trials. EXPENSES $452,697. INCLUDING GRANTS OF $452,697. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | Psychogenics Inc. Team has imported and is analyzing mouse and rat models of NGLY1 Deficiency for testing of candidate therapies. Team has conducted several studies using an NGLY1 knockout rat model to test phenotypic rescue using candidate small molecule therapies (both novel and approved drugs). EXPENSES $352,945. INCLUDING GRANTS OF $352,945. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | The University of Texas Southwestern Medical Center (Yan Lab) Team continues work generating and characterizing several mouse models of NGLY1 Deficiency, including models in which the gene is inactivated in certain tissues and conditionally after birth. These mouse models have allowed them to characterize neurological phenotypes including neuronal loss, neuropathological changes, inflammation, sensory and motor defects, and disease associated biomarkers, all of which are also observed in NGLY1 Deficiency patients These animal models provide a foundation for testing candidate therapies, including gene therapies and small molecule drugs. The team has also found that NGLY1 Deficiency in mice triggers a specific innate immune pathway mediated by the cGAS/STING pathway. Using genetic and pharmacological approaches, the team has uncovered three different targets that can be modulated to reduce disease associated phenotypes and improve survival. EXPENSES $203,574. INCLUDING GRANTS OF $203,574. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | The University of North Carolina (Hantman Lab) Team has utilized a mouse model on NGLY1 Deficiency to analyze directed movement behavior and identify the affected brain circuits responsible for the movement phenotypes charcateristic of NGLY1 Deficiency. The studies involve training wild type and Ngly1-deficient mice to perform a "reach-grab" task, comparing the task performance and movement dynamics between typical and affected animals, and recording from specific brain circuits while the animals perform the task. Identified changes will help to better understand the neural basis of the NGLY1 Deficiency movement disorder, define the neural circuits that must be targeted to treat the disease, and establish a platform to test potential therapies. EXPENSES $80,637. INCLUDING GRANTS OF $80,637. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | Charles River Laboratories Team has imported and is maintaining a colony of Ngly1 knockout rats for use in evaluating therapies to treat NGLY1 Deficiency. This knockout model has been a key foundation to test adeno-associated virus (AAV)-mediated gene delivery for rescue of disease-associated phenotypes and has supported an investigational new drug (IND) application to the FDA for an NGLY1 Deficiency gene therapy clinical study. Team has also conducted a study to monitor clinical phenotypes and collect biological samples in homozygous mutant and heterozygous (carrier) NGLY1 knockout rats across the lifespan from birth to eighteen months of age, and has continued to produce Ngly1 KO animals for use in in vivo drug testing studies. EXPENSES $68,025. INCLUDING GRANTS OF $68,025. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | Boston Children's Hospital (Yu Lab) TEAM HAS CONCEIVED AND TESTED METHODS TO USE DESIGNER ANTISENSE OLIGONUCLEOTIDES (ASOS) TO INHIBIT POTENTIAL TARGETS FOR NGLY1 THERAPY DEVELOPMENT. THIS RESEARCH HAS DEVELOPED CELLULAR MODELS TO MEASURE INHIBITION OF A SPECIFIC GENE TARGET WHOSE INACTIVATION HAS BEEN SHOWN TO R ESCUE NGLY1 LOSS. PILOT SCREENS WERE CONDUCTED AND OPTIMIZED ASOS HAVEBEEN IDENTIFIED. TEAM IS RESEARCHING METHODS TO ASSESS RESCUE OF NGLY1 DEFICIENCY PHENOTYPES UPON ASO TREATMENT. EXPENSES $49,108. INCLUDING GRANTS OF $49,108. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | HILLTOP LAB ANIMALS, INC. TEAM HAS IMPORTED AND ESTABLISHED A COLONY OF NGLY1 KNOCKOUT MICE FOR USE IN TESTING THERAPIES TO TREAT NGLY1 DEFICIENCY. A BREEDING COLONY HAS BEEN ESTABLISHED, AND MUTANT PHENOTYPES HAVE BEEN CHARACTERIZED. THIS MODEL SYSTEM HAS BEEN USED TO TEST DRUG CANDIDATES FOR THEIR ABILITY TO RESCUE NGLY1 DEFICIENCY-ASSOCIATED NEUROLOGICAL SYMPTOMS AND FOR GENETIC STUDIES TO TEST WHETHER BLOCKING OTHER PATHWAYS (INCLUDING FBXO6) HAS POTENTIAL TO TREAT NGLY1 DEFICIENCY. EXPENSES $27,695. INCLUDING GRANTS OF $27,695. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | ALBERT EINSTEIN COLLEGE OF MEDICINE (KAUSHIK LAB) TEAM IS TESTING THE HYPOTHESIS THAT DEFECTS IN NGLY1 FUNCTION LEADS TO THE IMPAIRMENT OF CELLULAR PROTEOSTASIS PATHWAYS THAT RECOGNIZE AND CLEAR MISFOLDED AND AGGREGATED PROTEINS AND DEFECTIVE ORGANELLES. USING NGLY1 KNOCKOUT RAT AND MOUSE TISSUES, NGLY1 MUTANT CELL LINES, AND NGLY1 DEFICIENCY PATIENT FIBROBLASTS, THE TEAM HAS OBSERVED SIGNIFICANT IMPAIRMENT IN MACRO- AND CHAPERONE MEDIATED-AUTOPHAGY AND DEFECTS IN LYSOSOMAL BIOGENESIS. THESE RESULTS HIGHLIGHT THE POTENTIAL OF DRUGS THAT TARGET THE AUTOPHAGY-LYSOSOME PATHWAY TO REVERSE CELLULAR DEFECTS ASSOCIATED WITH NGLY1 DEFICIENCY. THE TEAM HAS BEGUN EVALUATING DRUG-LIKE CHEMICAL MODULATORS OF THE AUTOPHAGY-LYSOSOMAL SYSTEM FOR THEIR ABILITY TO REDUCE CELLULAR PROTEOTOXICITY IN NGLY1 DEFICIENCY MODELS. EXPENSES $24,241. INCLUDING GRANTS OF $24,241. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | PURDUE UNIVERSITY (ROCHET LAB) TEAM IS DEVELOPING AND EMPLOYING CELLULAR MODELS TO TEST WHETHER NGLY1 AND ITS SUBSTRATE NFE2L1 HAVE A ROLE IN MODULATING CELLULAR STRESS AND PREVENTING OR CLEARING PROTEIN AGGREGATES IN THE BRAIN. THESE STUDIES ARE TESTING WHETHER LOSS OR DYSFUNCTION OF THE NGLY1-NFE2L1 PATHWAY MAY SENSITIZE NERVE CELLS TO OXIDATIVE OR PROTEIN MISFOLDING STRESS, LEADING TO NEURONAL DAMAGE AND NEURODEGENERATION. IN ADDITION, THE TEAM IS TESTING THE IDEA THAT ENHANCING NGLY1-NFE2L1 ACTIVITY CAN PREVENT OR SLOW NEURONAL LOSS USING CELLULAR MODELS OF PARKINSON'S DISEASE, A NEURODEGENERATIVE DISORDER ASSOCIATED WITH OXIDATIVE STRESS AND PROTEIN AGGREGATION. THESE STUDIES AIM TO UNDERSTAND THE CAUSE OF NEUROTOXICITY IN RARE AND COMMON NEURODEGENERATIVE DISORDERS, EXPLORE MECHANISMS SHARED BETWEEN NGLY1 DEFICIENCY AND PARKINSON'S DISEASE, AND PROVIDE INSIGHTS FOR THE DEVELOPMENT OF DISEASE-MODIFYING NEUROPROTECTIVE THERAPIES. EXPENSES $23,869. INCLUDING GRANTS OF $23,869. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | PHARMARON, INC TEAM HAS CONDUCTED PHARMACOLOGY STUDIES TO SUPPORT IN VIVO TESTING OF SMALL MOLECULE THERAPIES FOR NGLY1 DEFICIENCY. EXPENSES $20,356. INCLUDING GRANTS OF $20,356. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | UNIVERSITRY OF UTAH (CHOW LAB) TEAM HAS DEVELOPED AND IMPORTED MODEL ORGANISM AND HUMAN CELLULAR MODELS OF NGLY1 DEFICIENCY, CHARACTERIZED THEIR ABNORMALITIES AND BEGUN TO USE THESE TO INVESTIGATE CANDIDATE THERAPEUTIC TARGETS OF THIS RARE DISEASE. IN PARTICULAR THE TEAM IS TESTING PREVIOUSLY IDENTIFIED DRUG HITS AND INHIBITORS OF GLYCOGEN SYNTHASE 3-BETA (GSK3B) IN CELLULAR MODELS OF NGLY1 DEFICIENCY, AND IN FLY AND MOUSE MODELS OF NGLY1 DEFICIENCY. EXPENSES $19,321. INCLUDING GRANTS OF $19,321. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | BIOAGILYTIX LABS - vendor has conducted biomarker and immune profiling of NGLY1 Deficiency patients in support of NGLY1 Deficiency natural history studies. EXPENSES $19,000. INCLUDING GRANTS OF $0. REVENUE $0. TRANSNETYX - vendor has provided genotyping services to support animal breeding and functional studies at Hilltop Lab Animals and Psychogenics, Inc. EXPENSES $13,904. INCLUDING GRANTS OF $0. REVENUE $0. WUXI APPTEC - vendor has synthesized and characterized small molecule drug candidates for in vivo studies. EXPENSES $10,481. INCLUDING GRANTS OF $0. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | STANFORD UNIVERSITY DIXON AND BERTOZZI LABORATORIES) TEAM HAS CHARACTERIZED THE ROLE OF FERROPTOSIS, A FORM OF CELL DEATH ASSOCIATED WITH OXIDATIVE STRESS, IN THE PATHOLOGIES ASSOCIATED WITH NGLY1 DEFICIENCY. THIS STUDY HAS ESTABLISHED THAT LOSS OF NGLY1 OR ITS SUBSTRATE NFE2L1 SENSITIZES CELLS TO FERROPTOSIS, AND THIS FERROPTOSIS SENSITIVITY CAN BE REVERSED BY EXPRESSION OF AN ACTIVATED FORM OF NFE2L1 MIMICKING THAT GENERATED BY NGLY1-CATALYZED PROTEIN MODIFICATION. THESE STUDIES MAY HELP EXPLAIN THE CAUSES OF CELL DYSFUNCTION AND LOSS IN NGLY1 DEFICIENCY AND SUGGEST POTENTIAL TARGETS FOR CANDIDATE THERAPY DEVELOPMENT. EXPENSES $10,115. INCLUDING GRANTS OF $10,115. REVENUE $0. |
| FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES | UNIVERSITY OF HOUSTON - Team has conducted a pilot movement disorder study to systematically and quantitatively assess movement disorder characteristics of individual patients with NGLY1 Deficiency. EXPENSES $9,747. INCLUDING GRANTS OF $9,747. REVENUE $0. MEDCHEM EXPRESS LLC - vendor has provided small molecule compounds for in vivo and in vitro studies. EXPENSES $5,369. INCLUDING GRANTS OF $0. REVENUE $0. |
| FORM 990, PART VI, SECTION A, LINE 2: | THE PRESIDENT OF THE FOUNDATION HAS IMMATERIAL OWNERSHIP INTEREST, IN THE INVESTMENTS OF FORTRESS AND SILVERLAKE, WHICH ARE MANAGED BY TWO OF THE DIRECTORS. |
| FORM 990, PART VI, SECTION A, LINE 7A: | THE PRESIDENT OF THE FOUNDATION HAS AUTHORITY TO ELECT ONE OR MORE MEMBERS OF THE GOVERNING BODY. |
| FORM 990, PART VI, SECTION A, LINE 8A: | THE GOVERNING BODY OF THE FOUNDATION DID NOT MEET DURING THE YEAR. |
| FORM 990, PART VI, SECTION A, LINE 8B: | THE FOUNDATION DOES NOT HAVE ANY COMMITTEES. |
| FORM 990, PART VI, SECTION B, LINE 11B: | PRIOR TO FILING FORM 990, THE FOUNDATION'S PRESIDENT WILL REVIEW THE FORM. |
| FORM 990, PART VI, SECTION C, LINE 18: | AVAILABLE UPON REQUEST. |
| FORM 990, PART VI, SECTION C, LINE 19: | AVAILABLE UPON REQUEST. |
Comments